Co-Diagnostics shares are trading higher after the company announced that it submitted its Co-Dx PCR COVID-19 test with Co-Dx PCR Pro instrument for review by the FDA for Emergency Use Authorization.
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics shares are trading higher following the company's announcement of submitting its Co-Dx PCR COVID-19 test and Co-Dx PCR Pro instrument for FDA Emergency Use Authorization review.
December 27, 2023 | 4:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Co-Diagnostics' stock price is experiencing an uptick due to the company's submission of its COVID-19 test and instrument for FDA Emergency Use Authorization, signaling potential market expansion and increased sales.
The submission of Co-Diagnostics' COVID-19 test for FDA Emergency Use Authorization is a significant step towards commercialization, which could lead to increased sales and market share. This regulatory milestone typically generates positive investor sentiment, likely causing a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100